$66.09—Stale · unknown old
NYSE • Last print unknown ago
$66.09—Stale · unknown old
The SPDR S&P Pharmaceuticals ETF (XPH) provides exposure to the pharmaceutical sector, focusing on companies engaged in the research, development, manufacturing, and marketing of pharmaceuticals. It holds a diversified portfolio of large-cap pharmaceutical firms, primarily in North America, which are driven by innovation in drug development and regulatory approvals.
XPH generates revenue primarily through management fees based on the total assets under management. The ETF structure allows for lower expense ratios compared to actively managed funds, providing a competitive edge in cost efficiency. Its diversified holdings in leading pharmaceutical companies enhance its appeal to investors seeking exposure to the sector's growth.
Regulatory approvals for new drugs within the underlying pharmaceutical companies
Mergers and acquisitions activity in the pharmaceutical sector
Changes in healthcare policy affecting drug pricing and reimbursement
Market sentiment towards biotech and pharmaceutical innovation
Regulatory changes impacting drug pricing and access
Technological disruption in drug development processes
Increased competition from generic drugs and biosimilars
Emergence of new ETFs targeting the pharmaceutical sector
Market volatility affecting AUM and management fees
Potential liquidity risks during market downturns
moderate - The pharmaceutical sector is somewhat insulated from economic downturns due to the essential nature of healthcare, but overall spending can be affected by economic conditions.
Minimal impact from interest rates as the ETF's performance is primarily driven by equity market movements rather than financing costs.
minimal
growth - Investors looking for exposure to the pharmaceutical sector's innovation and growth potential.
moderate - Historical volatility aligns with the broader equity market, with some sensitivity to sector-specific news.